Hydroxyurea in Sickle Cell Disease: Coagulation and Activation in an Observational Study

20260 citationsJournal Articlegold Open Access

Authors

Munira Borhany · National Institute Of Blood Disease and Bone Marrow Transplantation

Hafiza Tuba Iqbal · National Institute Of Blood Disease and Bone Marrow Transplantation

Madiha Abid · National Institute Of Blood Disease and Bone Marrow Transplantation

Sidra Zafar · National Institute Of Blood Disease and Bone Marrow Transplantation

Abstract

This study demonstrates that HU therapy in Pakistani SCD patients significantly reduces D-dimer levels, suggesting reduced thrombotic activity. While the endothelial marker VCAM-1 showed no significant change, the rise in HbF is consistent with known HU effects.

Topics & Keywords

Hemoglobinopathies and Related Disorders Myeloproliferative Neoplasms: Diagnosis and Treatment Blood groups and transfusion

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Clinical Medicine Insights Pediatrics

DOI: 10.1177/11795565251403177

Field-Weighted Citation Impact: 0.00